Stratton, M. R., Campbell, P. J. & Andrew Futreal, P. The cancer genome. Nature 458 719–724 (2009).
Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899 (2010).
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002).
Borcoman, E., Nandikolla, A., Long, G., Goel, S. & Le Tourneau, C. Patterns Of Response And Progression To Immunotherapy. p. 169–178 (American Society of Clinical Oncology Educational Book, 2018).
Miao, D. & Van Allen, E. M. Genomic determinants of cancer immunotherapy. Curr. Opin. Immunol. 41, 32–38 (2016).
Mangino, M., Roederer, M., Beddall, M. H., Nestle, F. O. & Spector, T. D. Innate and adaptive immune traits are differentially affected by genetic and environmental factors. Nat. Commun. 8, 13850 (2017).
Orrù, V. et al. Genetic variants regulating immune cell levels in health and disease. Cell 155, 242–256 (2013).
Shahamatdar, S. et al. Germline features associated with immune infiltration in solid tumors. Cell Rep. 30, 2900–2908.e4 (2020).
Sayaman, R. W. et al. Germline genetic contribution to the immune landscape of cancer. Immunity 54, 367–386.e8 (2021).
Khan, Z. et al. Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. Proc. Natl Acad. Sci. USA 117, 12288–12294 (2020).
Milanese, J.-S. et al. Germline variants associated with leukocyte genes predict tumor recurrence in breast cancer patients. NPJ Precis. Oncol. 3, 28 (2019).
Kogan, D., Grabner, A., Yanucil, C., Faul, C. & Ulaganathan, V. K. STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion. J. Clin. Invest. 128, 1867–1872 (2018).
Marty, R. et al. MHC-I genotype restricts the oncogenic mutational landscape. Cell 171, 1272–1283.e15 (2017).
Marty Pyke, R. et al. Evolutionary pressure against MHC class II binding cancer mutations. Cell 175, 1991 (2018).
Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat. Med. 25, 1715–1720 (2019).
Arce Vargas, F. et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33, 649–663.e4 (2018).
Chowell, D. et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359, 582–587 (2018).
Queirolo, P. et al. Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: an italian melanoma intergroup study. Front. Immunol. 8, 386 (2017).
Uccellini, L. et al. IRF5 gene polymorphisms in melanoma. J. Transl. Med. 10, 170 (2012).
Bedognetti, D. et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br. J. Cancer 109, 2412–2423 (2013).
Ugurel, S. et al. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol. Immunother. 57, 685–691 (2008).
Geeleher, P. et al. Cancer expression quantitative trait loci (eQTLs) can be determined from heterogeneous tumor gene expression data by modeling variation in tumor purity. Genome Biol. 19, 130 (2018).
Lim, Y. W. et al. Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration. Proc. Natl Acad. Sci. USA 115, E11701–E11710 (2018).
Schmiedel, B. J. et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell 175, 1701–1715.e16 (2018).
Hauberg, M. E. et al. Large-scale identification of common trait and disease variants affecting gene expression. Am. J. Hum. Genet. 101, 157 (2017).
Hormozdiari, F. et al. Colocalization of GWAS and eQTL signals detects target genes. Am. J. Hum. Genet. 99, 1245–1260 (2016).
Speed, D., Hemani, G., Johnson, M. R. & Balding, D. J. Improved heritability estimation from genome-wide SNPs. Am. J. Hum. Genet. 91, 1011–1021 (2012).
Wang, Y., Xu, H., Zhu, B., Qiu, Z. & Lin, Z. Systematic identification of the key candidate genes in breast cancer stroma. Cell. Mol. Biol. Lett. 23, 44 (2018).
Korah, R., Boots, M. & Wieder, R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res. 64, 4514–4522 (2004).
Sun, Y. et al. High expression of fibronectin 1 indicates poor prognosis in gastric cancer. Oncol. Lett. 19, 93–102 (2020).
Lu, S., Simin, K., Khan, A. & Mercurio, A. M. Analysis of integrin β4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin. Cancer Res. 14, 1050–1058 (2008).
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
GTEx Consortium The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318–1330 (2020).
Bryois, J. et al. Cis and trans effects of human genomic variants on gene expression. PLoS Genet. 10, e1004461 (2014).
Tian, C. et al. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. Nat. Commun. 8, 599 (2017).
Knight, J. et al. Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Hum. Mol. Genet. 21, 5185–5192 (2012).
Aguiar, V. R. C., Masotti, C., Camargo, A. A. & Meyer, D. HLApers: HLA typing and quantification of expression with personalized index. Methods Mol. Biol. 2120, 101–112 (2020).
Degenhardt, F. et al. Construction and benchmarking of a multi-ethnic reference panel for the imputation of HLA class I and II alleles. Hum. Mol. Genet. 28, 2078–2092 (2019).
Furukawa, H. et al. The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases. Genes Immun. 18, 1–7 (2017).
Miretti, M. M. et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 76, 634–646 (2005).
Thorsson, V. et al. The immune landscape of cancer. Immunity 51, 411–412 (2019).
Ostendorf, B. N. et al. Common germline variants of the human APOE gene modulate melanoma progression and survival. Nat. Med. 26, 1048–1053 (2020).
Zhang, Y. et al. The cancer-associated genetic variant Rs3903072 modulates immune cells in the tumor microenvironment. Front. Genet. 10, 754 (2019).
Yoshida, H. et al. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade. Eur. J. Cancer 144, 317–325 (2021).
Kula, A., Dawidowicz, M., Kiczmer, P., Prawdzic Seńkowska, A. & Świętochowska, E. The role of genetic polymorphism within PD-L1 gene in cancer. Review. Exp. Mol. Pathol. 116, 104494 (2020).
Salmaninejad, A. et al. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics 70, 73–86 (2018).
Sasaki, H. et al. PD‑1 gene promoter polymorphisms correlate with a poor prognosis in non‑small cell lung cancer. Mol. Clin. Oncol. 2, 1035–1042 (2014).
Tang, W. et al. Programmed death-1 (PD-1) polymorphism is associated with gastric cardia adenocarcinoma. Int. J. Clin. Exp. Med. 8, 8086–8093 (2015).
Sayaman, R. W. et al. Germline genetic contribution to the immune landscape of cancer. Immunity 54, 367–386.e8 (2021).
Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92–94 (2017).
Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31, 3555–3557 (2015).
Myers, T. A., Chanock, S. J. & Machiela, M. J. LDlinkR: an R package for rapidly calculating linkage disequilibrium statistics in diverse populations. Front. Genet. 11, 157 (2020).
Karnes, J. H. et al. Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Sci. Transl. Med. 9, eaai8708 (2017).
Hugo, W. et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165, 35–44 (2016).
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949.e16 (2017).
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
de Bakker, P. I. W. et al. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum. Mol. Genet. 17, R122–R128 (2008).
Kreiner-Møller, E., Medina-Gomez, C., Uitterlinden, A. G., Rivadeneira, F. & Estrada, K. Improving accuracy of rare variant imputation with a two-step imputation approach. Eur. J. Hum. Genet. 23, 395–400 (2015).
Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
Elgart, M. et al. Non-linear machine learning models incorporating SNPs and PRS improve polygenic prediction in diverse human populations. Commun. Biol. 5, 856 (2022).
Wolchok, J. D. et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J. Clin. Oncol. 39, 9506–9506 (2021).
Maleki Vareki, S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J. Immunother. Cancer 6, 157 (2018).
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
Li, C. et al. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int. J. Cancer 122, 2077–2084 (2008).
Al Olama, A. A. et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat. Genet. 46, 1103–1109 (2014).
Zhang, T. et al. Genomic and evolutionary classification of lung cancer in never smokers. Nat. Genet. 53, 1348–1359 (2021).
Caronni, N. et al. Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer. Cancer Res. 78, 1685–1699 (2018).
Hemphill, W. O. et al. TREX1 as a novel immunotherapeutic target. Front. Immunol. 12, 660184 (2021).
Chowdhury, D. et al. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol. Cell 23, 133–142 (2006).
Wang, L. et al. Homoharringtonine could induce quick protein synthesis of PSMD11 through activating MEK1/ERK1/2 signaling pathway in pancreatic cancer cells. J. Cell. Biochem. 119, 6644–6656 (2018).
Bararia, D. et al. Alterations induce a tumor-promoting immune microenvironment in follicular lymphoma. Cell Rep. 31, 107522 (2020).
Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).
Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 21, 381–395 (2011).
McVicker, G. et al. Identification of genetic variants that affect histone modifications in human cells. Science 342, 747–749 (2013).
Creyghton, M. P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl Acad. Sci. USA 107, 21931–21936 (2010).
Liang, G. et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc. Natl Acad. Sci. USA 101, 7357–7362 (2004).
Sasidharan Nair, V. et al. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin. Epigenet. 10, 78 (2018).
Kim-Hellmuth, S. et al. Cell type-specific genetic regulation of gene expression across human tissues. Science 369, eaaz8528 (2020).
Martín-Cófreces, N. B. & Sánchez-Madrid, F. Sailing to and docking at the immune synapse: role of tubulin dynamics and molecular motors. Front. Immunol. 9, 1174 (2018).
Chamoto, K., Hatae, R. & Honjo, T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int. J. Clin. Oncol. 25, 790–800 (2020).
Sweis, R. F. & Luke, J. J. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol. Res. 120, 1–9 (2017).
Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895 (1992).
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
Greten, F. R. & Grivennikov, S. I. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51, 27–41 (2019).
Pelly, V. S. et al. Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. Cancer Discov. 11, 2602–2619 (2021).
Vyas, J. M., Van der Veen, A. G. & Ploegh, H. L. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8, 607–618 (2008).
Saric, T. et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 3, 1169–1176 (2002).
Hill, L. D. et al. Fetal ERAP2 variation is associated with preeclampsia in African Americans in a case-control study. BMC Med. Genet. 12, 64 (2011).
Cagliani, R. et al. Genetic diversity at endoplasmic reticulum aminopeptidases is maintained by balancing selection and is associated with natural resistance to HIV-1 infection. Hum. Mol. Genet. 19, 4705–4714 (2010).
Liu, S. et al. The ERAP gene is associated with HCV chronic infection in a Chinese Han population. Hum. Immunol. 78, 731–738 (2017).
Yao, Y. et al. Single nucleotide polymorphisms of the ERAP1 gene and risk of NSCLC: a comparison of genetically distant populations, chinese and caucasian. Arch. Immunol. Ther. Exp. 64, 117–122 (2016).
Mehta, A. M. et al. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 46, 577–586 (2007).
Mehta, A. M. et al. Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. Genes Chromosomes Cancer 48, 410–418 (2009).
Mehta, A. M. et al. Differences in genetic variation in antigen-processing machinery components and association with cervical carcinoma risk in two Indonesian populations. Immunogenetics 67, 267–275 (2015).
Dheilly, E. et al. Cathepsin S regulates antigen processing and T cell activity in non-hodgkin lymphoma. Cancer Cell 37, 674–689.e12 (2020).
Stultz, J. & Fong, L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 24, 697–717 (2021).
Yarchoan, M. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4, e126908 (2019).
Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat. Commun. 7, 10582 (2016).
Bilusic, M., Madan, R. A. & Gulley, J. L. Immunotherapy of prostate cancer: facts and hopes. Clin. Cancer Res. 23, 6764–6770 (2017).
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
Castro, A., Zanetti, M. & Carter, H. Neoantigen controversies. Annu Rev. Biomed. Data Sci. 4, 227–253 (2021).
Brightman, S. E., Naradikian, M. S., Miller, A. M. & Schoenberger, S. P. Harnessing neoantigen specific CD4 T cells for cancer immunotherapy. J. Leukoc. Biol. 107, 625–633 (2020).
Janssen, E. M. et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421, 852–856 (2003).
Sepich-Poore, G. D. et al. The microbiome and human cancer. Science 371, eabc4552 (2021).
Riquelme, E. et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178, 795–806.e12 (2019).
Fu, A. et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell 185, 1356–1372.e26 (2022).
Parhi, L. et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat. Commun. 11, 3259 (2020).
Brown, R. et al. Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics. Respir. Res. 21, 111 (2020).
Riether, C. & Ochsenbein, A. F. Genetic alterations impact immune microenvironment interactions in follicular lymphoma. Cancer Cell 37, 621–622 (2020).
Wei, L., Shao, N., Peng, Y. & Zhou, P. Inhibition of cathepsin S restores TGF-β-induced epithelial-to-mesenchymal transition and tight junction turnover in glioblastoma cells. J. Cancer 12, 1592–1603 (2021).
Fei, M. et al. Inhibition of cathepsin S induces mitochondrial apoptosis in glioblastoma cell lines through mitochondrial stress and autophagosome accumulation. Front. Oncol. 10, 516746 (2020).
Kim, E. H., Wong, S.-W. & Martinez, J. Programmed necrosis and disease: we interrupt your regular programming to bring you necroinflammation. Cell Death Differ. 26, 25–40 (2019).
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
de Velasco, G. et al. Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups. Cancer Immunol. Res 4, 820–822 (2016).
Hellmann, M. D. et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N. Engl. J. Med. 378, 2093–2104 (2018).
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).
Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77, 3540–3550 (2017).
Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447–3452 (2016).
Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60–65 (2017).
Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404.e9 (2016).
McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271.e11 (2017).
Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
Jafarpour, S. et al. Association of rare variants in genes of immune regulation with pediatric autoimmune CNS diseases. J. Neurol. 269, 6512–6529 (2022).
Liu, P. et al. Rare variants in inborn errors of immunity genes associated with Covid-19 severity. Front. Cell. Infect. Microbiol. 12, 888582 (2022).
Grulich, A. E., van Leeuwen, M. T., Falster, M. O. & Vajdic, C. M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370, 59–67 (2007).
Maranville, J. C. & Cox, N. J. Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits. Pharmacogenomics J. 16, 388–392 (2016).
Tin, A. et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat. Genet. 51, 1459–1474 (2019).
Carter, H. et al. Interaction landscape of inherited polymorphisms with somatic events in cancer. Cancer Discov. 7, 410–423 (2017).
Korn, J. M. et al. Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat. Genet. 40, 1253–1260 (2008).
Das, S. et al. Next-generation genotype imputation service and methods. Nat. Genet. 48, 1284–1287 (2016).
Kuhn, R. M., Haussler, D. & Kent, W. J. The UCSC genome browser and associated tools. Brief. Bioinform. 14, 144–161 (2013).
Bellenguez, C. et al. A robust clustering algorithm for identifying problematic samples in genome-wide association studies. Bioinformatics 28, 134–135 (2012).
Danaher, P. et al. Gene expression markers of Tumor Infiltrating Leukocytes. J. Immunother. Cancer 5, 18 (2017).
Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773–782 (2019).
Yang, J. et al. FTO genotype is associated with phenotypic variability of body mass index. Nature 490, 267–272 (2012).
Aguiar, V. R. C., César, J., Delaneau, O., Dermitzakis, E. T. & Meyer, D. Expression estimation and eQTL mapping for HLA genes with a personalized pipeline. PLoS Genet. 15, e1008091 (2019).
Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766–D773 (2019).
Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2011).
Yang, J. et al. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42, 565–569 (2010).
Seabold, S. & Perktold, J. Statsmodels: econometric and statistical modeling with python. Proceedings of the 9th Python in Science Conference. Preprint at https://doi.org/10.25080/majora-92bf1922-011 (2010).
Zhang, Y.-B. et al. Genome-wide association study identifies multiple susceptibility loci for craniofacial microsomia. Nat. Commun. 7, 10605 (2016).
McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).
Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).
Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc.: Ser. B (Methodol.) 58, 267–288 (1996).
Chen, T. & Guestrin, C. XGBoost. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (ACM, 2016). https://doi.org/10.1145/2939672.2939785.
Mann, H. B. & Whitney, D. R. On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat. 18, 50–60 (1947).
Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-scale genotype datasets. Bioinformatics 33, 2776–2778 (2017).
Hall, M. A. et al. PLATO software provides analytic framework for investigating complexity beyond genome-wide association studies. Nat. Commun. 8, 1167 (2017).
Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400–416.e11 (2018).
Li, C. et al. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum. Mutat. 29, 1443–1451 (2008).
Conti, D. V. et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat. Genet. 53, 65–75 (2021).
Poplin, R. et al. Scaling accurate genetic variant discovery to tens of thousands of samples. Preprint at https://doi.org/10.1101/201178.
Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018).
Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589–595 (2010).
Li, H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 27, 2987–2993 (2011).
Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Auwera, G. A. et al. From FastQ data to high‐confidence variant calls: the genome analysis toolkit best practices pipeline. Curr. Protoc. Bioinform. 43, 11.10.1–11.10.33 (2013).
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
Poplin, R. et al. A universal SNP and small-indel variant caller using deep neural networks. Nat. Biotechnol. 36, 983–987 (2018).
Yun, T. et al. Accurate, scalable cohort variant calls using DeepVariant and GLnexus. Bioinformatics 36, 5582–5589 (2021).
Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143–e152 (2017).
Edwards, J. A. & Edwards, R. A. Fastq-pair: efficient synchronization of paired-end fastq files. Preprint at https://doi.org/10.1101/552885.
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 12, 323 (2011).
Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304.e6 (2018).
Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018).
Schumacher, F. R. et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat. Genet. 50, 928–936 (2018).
Sears, T. J. & hcarter. cartercompbio/TIMEgermline: Publication Release. Zenodo https://doi.org/10.5281/ZENODO.7792786. (2023)